Verve is meeting this challenge head-on through the development of groundbreaking, single-course gene editing medicines. Cardiovascular disease (CVD) is the leading cause of death, …

16 hours ago · Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform …

3 hours ago · Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion, the companies said on Tuesday, to boost its pipeline of experimental medicines beyond its …

17 hours ago · Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition by the world’s most valuable drugmaker as it seeks to …

3 hours ago · By the numbers: Lilly is paying $10.50 per share, or about $1 billion, in cash for Verve, representing a 113% premium to Verve's 30-day volume-weighted average stock price …

4 hours ago · Shares of Verve jumped 78%, to $11.19, in premarket trading Tuesday. The stock is up 19% in the past year. Lilly shares edged 1% lower, to $799.44, in premarket trading and …

4 hours ago · Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease. Lilly will acquire Verve for $10.50 per share, …

5 hours ago · Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its weight-loss and diabetes drugs.

May 2, 2025 · Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform …

5 hours ago · Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for up to $1.3 billion in the obesity drug maker’s …